Exact Mass: 510.4284018
Exact Mass Matches: 510.4284018
Found 289 metabolites which its exact mass value is equals to given mass value 510.4284018
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Gallamine Triethiodide
A synthetic nondepolarizing blocking drug. The actions of gallamine triethiodide are similar to those of tubocurarine, but this agent blocks the cardiac vagus and may cause sinus tachycardia and, occasionally, hypertension and increased cardiac output. It should be used cautiously in patients at risk from increased heart rate but may be preferred for patients with bradycardia. (From AMA Drug Evaluations Annual, 1992, p198)
Nb-Lignoceroyltryptamine
Nb-Lignoceroyltryptamine is found in alcoholic beverages. Nb-Lignoceroyltryptamine is an alkaloid from seeds of Annona reticulata (custard apple) and Rollina mucosa (biriba). Alkaloid from seeds of Annona reticulata (custard apple) and Rollina mucosa (biriba). Nb-Lignoceroyltryptamine is found in alcoholic beverages and fruits.
Nervonyl carnitine
C31H60NO4 (510.45221000000004)
Nervonyl carnitine is an acylcarnitine. Numerous disorders have been described that lead to disturbances in energy production and in intermediary metabolism in the organism which are characterized by the production and excretion of unusual acylcarnitines. A mutation in the gene coding for carnitine-acylcarnitine translocase or the OCTN2 transporter aetiologically causes a carnitine deficiency that results in poor intestinal absorption of dietary L-carnitine, its impaired reabsorption by the kidney and, consequently, in increased urinary loss of L-carnitine. Determination of the qualitative pattern of acylcarnitines can be of diagnostic and therapeutic importance. The betaine structure of carnitine requires special analytical procedures for recording. The ionic nature of L-carnitine causes a high water solubility which decreases with increasing chain length of the ester group in the acylcarnitines. Therefore, the distribution of L-carnitine and acylcarnitines in various organs is defined by their function and their physico-chemical properties as well. High performance liquid chromatography (HPLC) permits screening for free and total carnitine, as well as complete quantitative acylcarnitine determination, including the long-chain acylcarnitine profile. (PMID: 17508264, Monatshefte fuer Chemie (2005), 136(8), 1279-1291., Int J Mass Spectrom. 1999;188:39-52.).
DG(14:0/14:1(9Z)/0:0)
DG(14:0/14:1(9Z)/0:0) is a diglyceride, or a diacylglycerol (DAG). It is a glyceride consisting of two fatty acid chains covalently bonded to a glycerol molecule through ester linkages. Diacylglycerols can have many different combinations of fatty acids attached at both the C-1 and C-2 positions. DG(14:0/14:1(9Z)/0:0), in particular, consists of one chain of myristic acid at the C-1 position and one chain of myristoleic acid at the C-2 position. The myristic acid moiety is derived from nutmeg and butter, while the myristoleic acid moiety is derived from milk fats. Mono- and diacylglycerols are common food additives used to blend together certain ingredients, such as oil and water, which would not otherwise blend well. Dacylglycerols are often found in bakery products, beverages, ice cream, chewing gum, shortening, whipped toppings, margarine, and confections. Synthesis of diacylglycerol begins with glycerol-3-phosphate, which is derived primarily from dihydroxyacetone phosphate, a product of glycolysis (usually in the cytoplasm of liver or adipose tissue cells). Glycerol-3-phosphate is first acylated with acyl-coenzyme A (acyl-CoA) to form lysophosphatidic acid, which is then acylated with another molecule of acyl-CoA to yield phosphatidic acid. Phosphatidic acid is then de-phosphorylated to form diacylglycerol.Diacylglycerols are precursors to triacylglycerols (triglyceride), which are formed by the addition of a third fatty acid to the diacylglycerol under the catalysis of diglyceride acyltransferase. Since diacylglycerols are synthesized via phosphatidic acid, they will usually contain a saturated fatty acid at the C-1 position on the glycerol moiety and an unsaturated fatty acid at the C-2 position. DG(14:0/14:1(9Z)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(14:0/14:1(9Z)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(14:1(9Z)/14:0/0:0)
DG(14:1(9Z)/14:0/0:0) is a diglyceride, or a diacylglycerol (DAG). It is a glyceride consisting of two fatty acid chains covalently bonded to a glycerol molecule through ester linkages. Diacylglycerols can have many different combinations of fatty acids attached at both the C-1 and C-2 positions. DG(14:1(9Z)/14:0/0:0), in particular, consists of one chain of myristoleic acid at the C-1 position and one chain of myristic acid at the C-2 position. The myristoleic acid moiety is derived from milk fats, while the myristic acid moiety is derived from nutmeg and butter. Mono- and diacylglycerols are common food additives used to blend together certain ingredients, such as oil and water, which would not otherwise blend well. Dacylglycerols are often found in bakery products, beverages, ice cream, chewing gum, shortening, whipped toppings, margarine, and confections. Synthesis of diacylglycerol begins with glycerol-3-phosphate, which is derived primarily from dihydroxyacetone phosphate, a product of glycolysis (usually in the cytoplasm of liver or adipose tissue cells). Glycerol-3-phosphate is first acylated with acyl-coenzyme A (acyl-CoA) to form lysophosphatidic acid, which is then acylated with another molecule of acyl-CoA to yield phosphatidic acid. Phosphatidic acid is then de-phosphorylated to form diacylglycerol.Diacylglycerols are precursors to triacylglycerols (triglyceride), which are formed by the addition of a third fatty acid to the diacylglycerol under the catalysis of diglyceride acyltransferase. Since diacylglycerols are synthesized via phosphatidic acid, they will usually contain a saturated fatty acid at the C-1 position on the glycerol moiety and an unsaturated fatty acid at the C-2 position.
Propylene glycol mono- and diesters of fats and fatty acids
Propylene glycol mono- and diesters of fats and fatty acids is used as a food additive [EAFUS] ("EAFUS: Everything Added to Food in the United States. [http://www.eafus.com/]") It is used as a food additive .
DG(14:0/0:0/14:1n5)
DG(14:0/0:0/14:1n5) is a diglyceride, or a diacylglycerol (DAG). It is a glyceride consisting of two fatty acid chains covalently bonded to a glycerol molecule through ester linkages. Diacylglycerols can have many different combinations of fatty acids attached at the C-1, C-2, or C-3 positions. DG(14:0/0:0/14:1n5), in particular, consists of one chain of myristic acid at the C-1 position and one chain of myristoleic acid at the C-3 position. The myristic acid moiety is derived from nutmeg and butter, while the myristoleic acid moiety is derived from milk fats. Mono- and diacylglycerols are common food additives used to blend together certain ingredients, such as oil and water, which would not otherwise blend well. Dacylglycerols are often found in bakery products, beverages, ice cream, chewing gum, shortening, whipped toppings, margarine, and confections.
Synthesis of diacylglycerol begins with glycerol-3-phosphate, which is derived primarily from dihydroxyacetone phosphate, a product of glycolysis (usually in the cytoplasm of liver or adipose tissue cells). Glycerol-3-phosphate is first acylated with acyl-coenzyme A (acyl-CoA) to form lysophosphatidic acid, which is then acylated with another molecule of acyl-CoA to yield phosphatidic acid. Phosphatidic acid is then de-phosphorylated to form diacylglycerol.
Diacylglycerols are precursors to triacylglycerols (triglyceride), which are formed by the addition of a third fatty acid to the diacylglycerol under the catalysis of diglyceride acyltransferase. Since diacylglycerols are synthesized via phosphatidic acid, they will usually contain a saturated fatty acid at the C-1 position on the glycerol moiety and an unsaturated fatty acid at the C-3 position.
FAHFA(16:0/9-O-16:0)
Branched fatty acid esters of hydroxy fatty acids (FAHFAs) are endogenous lipids found in adipose tissue and serum that correlate with insulin sensitivity and are reduced in insulin-resistant humans. Structurally, they are characterized by a branched ester linkage between a fatty acid and a hydroxy-fatty acid. Different positions of the branched ester on the hydroxy fatty acid results in different isomers. FAHFA(16:0/9-O-16:0), in particular, is formed from the condensation of the carboxy group of palmitic acid with the hydroxy group of 9-hydroxyhexadecanoic acid. It is alternatively named 9-PAHPA since it is the 9-hydroxy isomer of the PAHPA (palmitic acid-hydroxypalmitic acid) family.
FAHFA(16:0/5-O-16:0)
Branched fatty acid esters of hydroxy fatty acids (FAHFAs) are endogenous lipids found in adipose tissue and serum that correlate with insulin sensitivity and are reduced in insulin-resistant humans. Structurally, they are characterized by a branched ester linkage between a fatty acid and a hydroxy-fatty acid. Different positions of the branched ester on the hydroxy fatty acid results in different isomers. FAHFA(16:0/5-O-16:0), in particular, is formed from the condensation of the carboxy group of palmitic acid with the hydroxy group of 5-hydroxyhexadecanoic acid. It is alternatively named 5-PAHPA since it is the 5-hydroxy isomer of the PAHPA (palmitic acid-hydroxypalmitic acid) family.
FAHFA(16:0/7-O-16:0)
Branched fatty acid esters of hydroxy fatty acids (FAHFAs) are endogenous lipids found in adipose tissue and serum that correlate with insulin sensitivity and are reduced in insulin-resistant humans. Structurally, they are characterized by a branched ester linkage between a fatty acid and a hydroxy-fatty acid. Different positions of the branched ester on the hydroxy fatty acid results in different isomers. FAHFA(16:0/7-O-16:0), in particular, is formed from the condensation of the carboxy group of palmitic acid with the hydroxy group of 7-hydroxyhexadecanoic acid. It is alternatively named 7-PAHPA since it is the 7-hydroxy isomer of the PAHPA (palmitic acid-hydroxypalmitic acid) family.
FAHFA(16:0/8-O-16:0)
Branched fatty acid esters of hydroxy fatty acids (FAHFAs) are endogenous lipids found in adipose tissue and serum that correlate with insulin sensitivity and are reduced in insulin-resistant humans. Structurally, they are characterized by a branched ester linkage between a fatty acid and a hydroxy-fatty acid. Different positions of the branched ester on the hydroxy fatty acid results in different isomers. FAHFA(16:0/8-O-16:0), in particular, is formed from the condensation of the carboxy group of palmitic acid with the hydroxy group of 8-hydroxyhexadecanoic acid. It is alternatively named 8-PAHPA since it is the 8-hydroxy isomer of the PAHPA (palmitic acid-hydroxypalmitic acid) family.
FAHFA(16:0/10-O-16:0)
Branched fatty acid esters of hydroxy fatty acids (FAHFAs) are endogenous lipids found in adipose tissue and serum that correlate with insulin sensitivity and are reduced in insulin-resistant humans. Structurally, they are characterized by a branched ester linkage between a fatty acid and a hydroxy-fatty acid. Different positions of the branched ester on the hydroxy fatty acid results in different isomers. FAHFA(16:0/10-O-16:0), in particular, is formed from the condensation of the carboxy group of palmitic acid with the hydroxy group of 10-hydroxyhexadecanoic acid. It is alternatively named 10-PAHPA since it is the 10-hydroxy isomer of the PAHPA (palmitic acid-hydroxypalmitic acid) family.
FAHFA(16:0/11-O-16:0)
Branched fatty acid esters of hydroxy fatty acids (FAHFAs) are endogenous lipids found in adipose tissue and serum that correlate with insulin sensitivity and are reduced in insulin-resistant humans. Structurally, they are characterized by a branched ester linkage between a fatty acid and a hydroxy-fatty acid. Different positions of the branched ester on the hydroxy fatty acid results in different isomers. FAHFA(16:0/11-O-16:0), in particular, is formed from the condensation of the carboxy group of palmitic acid with the hydroxy group of 11-hydroxyhexadecanoic acid. It is alternatively named 11-PAHPA since it is the 11-hydroxy isomer of the PAHPA (palmitic acid-hydroxypalmitic acid) family.
FAHFA(16:0/12-O-16:0)
Branched fatty acid esters of hydroxy fatty acids (FAHFAs) are endogenous lipids found in adipose tissue and serum that correlate with insulin sensitivity and are reduced in insulin-resistant humans. Structurally, they are characterized by a branched ester linkage between a fatty acid and a hydroxy-fatty acid. Different positions of the branched ester on the hydroxy fatty acid results in different isomers. FAHFA(16:0/12-O-16:0), in particular, is formed from the condensation of the carboxy group of palmitic acid with the hydroxy group of 12-hydroxyhexadecanoic acid. It is alternatively named 12-PAHPA since it is the 12-hydroxy isomer of the PAHPA (palmitic acid-hydroxypalmitic acid) family.
FAHFA(16:0/13-O-16:0)
Branched fatty acid esters of hydroxy fatty acids (FAHFAs) are endogenous lipids found in adipose tissue and serum that correlate with insulin sensitivity and are reduced in insulin-resistant humans. Structurally, they are characterized by a branched ester linkage between a fatty acid and a hydroxy-fatty acid. Different positions of the branched ester on the hydroxy fatty acid results in different isomers. FAHFA(16:0/13-O-16:0), in particular, is formed from the condensation of the carboxy group of palmitic acid with the hydroxy group of 13-hydroxyhexadecanoic acid. It is alternatively named 13-PAHPA since it is the 13-hydroxy isomer of the PAHPA (palmitic acid-hydroxypalmitic acid) family.
FAHFA(16:0/6-O-16:0)
Branched fatty acid esters of hydroxy fatty acids (FAHFAs) are endogenous lipids found in adipose tissue and serum that correlate with insulin sensitivity and are reduced in insulin-resistant humans. Structurally, they are characterized by a branched ester linkage between a fatty acid and a hydroxy-fatty acid. Different positions of the branched ester on the hydroxy fatty acid results in different isomers. FAHFA(16:0/6-O-16:0), in particular, is formed from the condensation of the carboxy group of palmitic acid with the hydroxy group of 6-hydroxyhexadecanoic acid. It is alternatively named 6-PAHPA since it is the 6-hydroxy isomer of the PAHPA (palmitic acid-hydroxypalmitic acid) family.
3-O-Isovaleryl-beta-amyrin|beta-amyrin 3-methylbutanoate|beta-amyrin-3-(3-methylbutanonate)|beta-Amyrin-isovalerat
(3beta,6alpha,12beta,20S,24?鈥?-form-Dammarane-3,6,12,20,24,25-hexol
(4aR)-10c-Isocaleryloxy-1t.4ar.6at.6bc.9.9.12ac-heptamethyl-2-methylen-(8atH.12btH.14acH.14btH)-docosahydro-picen|3-Methybutanoyl-20(30)-Taraxasten-3-ol|3beta-Isovaleryloxy-18alpha.19betaH-ursen-(20(30))|3beta-Isovaleryloxy-taraxasten-(20(30))|Isovaleriansaeure-[taraxasten-(20(30))-yl-(3beta)-ester]|O-Isovaleryl-taraxasterol|psi-taraxasteryl-3-(3-methyl-butanoate)|Taraxasten-(20(30))-yl-(3beta)-isovalerat
(23S)-23-ethyl-24-methyl-cycloart-24(241)-en-3beta-yl acetate|Ac-23-Ethyl-24-methylenecycloartan-3-ol
Flaxedil
D018373 - Peripheral Nervous System Agents > D009465 - Neuromuscular Agents > D009466 - Neuromuscular Blocking Agents D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists
[(2R)-3-carboxy-2-[(Z)-tetracos-15-enoyl]oxypropyl]-trimethylazanium
C31H60NO4+ (510.45221000000004)
[3-carboxy-2-[(E)-tetracos-15-enoyl]oxypropyl]-trimethylazanium
C31H60NO4+ (510.45221000000004)
1-Decanoyl-2-oleoylglycerol
A 1,2-diglyceride in which the acyl groups at positions 1 and 2 are specified as decanoyl and oleoyl respectively.
[3-carboxy-2-[(E)-tetracos-11-enoyl]oxypropyl]-trimethylazanium
C31H60NO4+ (510.45221000000004)
N,N,N-Trimethyl-2-[[[(R)-3-(hexadecyloxy)-2-ethoxypropoxy]oxylato(oxo)phosphoranyl]oxy]ethane-1-aminium
C26H57NO6P+ (510.39232920000006)
1-Capryl-2-oleoyl-sn-glycerol
A 1,2-diacyl-sn-glycerol in which the 1- and 2-acyl groups are specified as capryl (decanoyl) and oleoyl (9Z-octadecenoyl) respectively.
1-Oleoyl-2-decanoyl-sn-glycerol
A 1,2-diacyl-sn-glycerol where oleoyl and decanoyl are the 1- and 2-acyl groups, respectively.
(3-decanoyloxy-2-hydroxypropyl) (Z)-octadec-9-enoate
2-[Hydroxy-(2-hydroxy-3-octadecoxypropoxy)phosphoryl]oxyethyl-trimethylazanium
C26H57NO6P+ (510.39232920000006)
[1-hydroxy-3-[(Z)-icos-11-enoxy]propan-2-yl] nonanoate
[1-[(Z)-hexacos-15-enoxy]-3-hydroxypropan-2-yl] propanoate
[1-hydroxy-3-[(Z)-tetracos-13-enoxy]propan-2-yl] pentanoate
[1-[(Z)-docos-13-enoxy]-3-hydroxypropan-2-yl] heptanoate
(1-hydroxy-3-octoxypropan-2-yl) (Z)-henicos-11-enoate
[1-[(Z)-henicos-11-enoxy]-3-hydroxypropan-2-yl] octanoate
(1-hydroxy-3-nonoxypropan-2-yl) (Z)-icos-11-enoate
(1-decoxy-3-hydroxypropan-2-yl) (Z)-nonadec-9-enoate
[1-hydroxy-3-[(Z)-nonadec-9-enoxy]propan-2-yl] decanoate
(1-hydroxy-3-tetradecoxypropan-2-yl) (Z)-pentadec-9-enoate
(1-hexadecoxy-3-hydroxypropan-2-yl) (Z)-tridec-9-enoate
[1-hydroxy-3-[(Z)-octadec-9-enoxy]propan-2-yl] undecanoate
(1-hydroxy-3-tridecoxypropan-2-yl) (Z)-hexadec-9-enoate
[1-[(Z)-hexadec-9-enoxy]-3-hydroxypropan-2-yl] tridecanoate
(1-hydroxy-3-pentadecoxypropan-2-yl) (Z)-tetradec-9-enoate
[1-[(Z)-heptadec-9-enoxy]-3-hydroxypropan-2-yl] dodecanoate
(1-dodecoxy-3-hydroxypropan-2-yl) (Z)-heptadec-9-enoate
[1-hydroxy-3-[(Z)-tridec-9-enoxy]propan-2-yl] hexadecanoate
[1-hydroxy-3-[(Z)-tetradec-9-enoxy]propan-2-yl] pentadecanoate
[1-hydroxy-3-[(Z)-pentadec-9-enoxy]propan-2-yl] tetradecanoate
(1-hydroxy-3-undecoxypropan-2-yl) (Z)-octadec-9-enoate
Pentadecanoic acid (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)-2,4,6,8-nonatetrenyl ester
(1-hydroxy-3-nonanoyloxypropan-2-yl) (Z)-nonadec-9-enoate
(1-hydroxy-3-undecanoyloxypropan-2-yl) (Z)-heptadec-9-enoate
[3-hydroxy-2-[(Z)-tridec-9-enoyl]oxypropyl] pentadecanoate
(1-dodecanoyloxy-3-hydroxypropan-2-yl) (Z)-hexadec-9-enoate
[3-hydroxy-2-[(Z)-tetradec-9-enoyl]oxypropyl] tetradecanoate
(1-hydroxy-3-tridecanoyloxypropan-2-yl) (Z)-pentadec-9-enoate
[(2S)-3-hydroxy-2-tridecanoyloxypropyl] (E)-pentadec-9-enoate
(1-heptanoyloxy-3-hydroxypropan-2-yl) (Z)-henicos-11-enoate
(1-acetyloxy-3-hydroxypropan-2-yl) (Z)-hexacos-15-enoate
(1-butanoyloxy-3-hydroxypropan-2-yl) (Z)-tetracos-13-enoate
(1-hydroxy-3-octanoyloxypropan-2-yl) (Z)-icos-11-enoate
(1-hexanoyloxy-3-hydroxypropan-2-yl) (Z)-docos-13-enoate
2-[Hydroxy-(3-hydroxy-2-octadecoxypropoxy)phosphoryl]oxyethyl-trimethylazanium
C26H57NO6P+ (510.39232920000006)
[(2S)-1-hydroxy-3-undecanoyloxypropan-2-yl] (E)-heptadec-9-enoate
[(2S)-3-hydroxy-2-undecanoyloxypropyl] (E)-heptadec-9-enoate
[(2S)-2-dodecanoyloxy-3-hydroxypropyl] (E)-hexadec-9-enoate
[(2S)-1-hydroxy-3-[(E)-tetradec-9-enoyl]oxypropan-2-yl] tetradecanoate
[1-carboxy-3-[2-hydroxy-3-[(10E,13E,16E)-nonadeca-10,13,16-trienoyl]oxypropoxy]propyl]-trimethylazanium
[(2S)-1-decanoyloxy-3-hydroxypropan-2-yl] (E)-octadec-11-enoate
[(2S)-1-dodecanoyloxy-3-hydroxypropan-2-yl] (E)-hexadec-9-enoate
[(2S)-3-hydroxy-2-[(E)-tetradec-9-enoyl]oxypropyl] tetradecanoate
[(2S)-1-hydroxy-3-tridecanoyloxypropan-2-yl] (E)-pentadec-9-enoate
[(2S)-2-decanoyloxy-3-hydroxypropyl] (E)-octadec-11-enoate
diacylglycerol 28:1
A diglyceride in which the two acyl groups contain a total of 28 carbons and 1 double bond.
TG(27:1)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
OAHFA(32:0)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
MG(29:1)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
Vitamin D3 octanoate
Vitamin D3 octanoate is an octanoate ester of vitamin D3[1]. Vitamin D3 (Cholecalciferol; HY-15398) is a naturally occuring form of vitamin D. Vitamin D3 induces cell differentiation and prevents proliferation of cancer cells[2].
2,6,10,15,19,23-hexamethyltetracosa-2,10,14,22-tetraene-1,6,7,18,19,24-hexol
(1s,2s,3r,4e,6z,9z,16s,18r,32s,33s)-2,3-dihydroxy-14,29-diazapentacyclo[16.14.1.0¹,¹⁴.0¹⁶,³².0²⁹,³³]tritriaconta-4,6,9-triene-18-carbaldehyde
(3s,4ar,6ar,6bs,8ar,12ar,14ar,14br)-4,4,6a,6b,8a,11,11,14b-octamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl 3-methylbutanoate
15-(5,5-dimethyl-6-methylideneoctan-2-yl)-7,7,12,16-tetramethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-6-yl acetate
(3s,4ar,6ar,6br,8ar,12bs,14ar,14br)-4,4,6a,6b,8a,11,11,14b-octamethyl-1,2,3,4a,5,6,7,8,9,10,12b,13,14,14a-tetradecahydropicen-3-yl pentanoate
4,4,6a,6b,8a,12,14b-heptamethyl-11-methylidene-hexadecahydropicen-3-yl 3-methylbutanoate
(2e,6r,7r,10e,14e,18s,19s,22e)-2,6,10,15,19,23-hexamethyltetracosa-2,10,14,22-tetraene-1,6,7,18,19,24-hexol
4,4,6b,8a,11,12,12b,14b-octamethyl-2,3,4a,5,6,7,8,9,10,11,12,12a,13,14-tetradecahydro-1h-picen-3-yl 3-methylbutanoate
(1s,3r,6s,8r,11s,12s,15r,16r)-7,7,12,16-tetramethyl-15-[(2r)-6-methylheptan-2-yl]pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-6-yl (2e)-2-methylbut-2-enoate
7-(dimethylamino)-1-{4-[1-(2-hydroxyethyl)-2,2-dimethylpyrrolidin-3-ylidene]butan-2-yl}-9a,11a-dimethyl-1h,2h,3h,3ah,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-6-one
C33H54N2O2 (510.41850639999996)
3a,5a,5b,8,8,11a-hexamethyl-1-(prop-1-en-2-yl)-hexadecahydrocyclopenta[a]chrysen-9-yl 3-oxobutanoate
(1r,3ar,5ar,5br,7ar,9s,11ar,11br,13ar,13br)-3a,5a,5b,8,8,11a-hexamethyl-1-(prop-1-en-2-yl)-hexadecahydrocyclopenta[a]chrysen-9-yl 3-oxobutanoate
7-(dimethylamino)-1-{4-[1-(2-hydroxyethyl)-2,2-dimethylpyrrolidin-3-ylidene]butan-2-yl}-9a,11a-dimethyl-1h,2h,3h,3ah,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-6-one
C33H54N2O2 (510.41850639999996)
(1r,7s,9as,11ar)-7-(dimethylamino)-1-[(2r)-4-[(3e)-1-(2-hydroxyethyl)-2,2-dimethylpyrrolidin-3-ylidene]butan-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-6-one
C33H54N2O2 (510.41850639999996)
(2e,10e,14e,22e)-2,6,10,15,19,23-hexamethyltetracosa-2,10,14,22-tetraene-1,6,7,18,19,24-hexol
3-[(7e)-10-(pyridin-3-yl)dec-7-en-1-yl]-1-[(8e)-10-(pyridin-3-yl)dec-8-en-1-yl]pyridin-1-ium
1,12-bis[5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-4,9-dimethyldodeca-4,8-diene-1,12-diol
(3s,4as,6bs,8ar,11r,12s,12ar,12bs,14bs)-4,4,6b,8a,11,12,12b,14b-octamethyl-2,3,4a,5,6,7,8,9,10,11,12,12a,13,14-tetradecahydro-1h-picen-3-yl 3-methylbutanoate
4,4,6a,6b,8a,11,11,14b-octamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl 3-methylbutanoate
(3s,4ar,6ar,6br,8ar,12s,12ar,12br,14ar,14br)-4,4,6a,6b,8a,12,14b-heptamethyl-11-methylidene-hexadecahydropicen-3-yl 3-methylbutanoate
3a,5a,5b,8,8,11a-hexamethyl-1-(prop-1-en-2-yl)-hexadecahydrocyclopenta[a]chrysen-9-yl 3-methylbutanoate
(3r,6as,6br,8ar,12ar,12bs,14ar,14bs)-4,4,6b,8a,11,11,12b,14a-octamethyl-1,2,3,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydropicen-3-yl (2r)-2-methylbutanoate
(1r,4e,8e,12r)-1-[(2r,5r)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-12-[(2s,5r)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-4,9-dimethyldodeca-4,8-diene-1,12-diol
4,4,6a,6b,8a,11,11,14b-octamethyl-1,2,3,4a,5,6,7,8,9,10,12b,13,14,14a-tetradecahydropicen-3-yl pentanoate
(1s,3r,6s,8s,11r,12s,15r,16r)-15-[(2r)-5,5-dimethyl-6-methylideneoctan-2-yl]-7,7,12,16-tetramethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-6-yl acetate
(1r,3ar,5ar,5br,7ar,9s,11ar,11br,13ar,13br)-3a,5a,5b,8,8,11a-hexamethyl-1-(prop-1-en-2-yl)-hexadecahydrocyclopenta[a]chrysen-9-yl 3-methylbutanoate
(1r,7s,9ar,11ar)-7-(dimethylamino)-1-[(2r)-4-[(3e)-1-(2-hydroxyethyl)-2,2-dimethylpyrrolidin-3-ylidene]butan-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-6-one
C33H54N2O2 (510.41850639999996)
(1s,3r,6s,12s,15r,16r)-15-[(2r,4s)-4-ethyl-6-methyl-5-methylideneheptan-2-yl]-7,7,12,16-tetramethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-6-yl acetate
(1s,3r,6s,8r,11s,12s,15r,16r)-15-[(2r)-5,5-dimethyl-6-methylideneoctan-2-yl]-7,7,12,16-tetramethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-6-yl acetate
15-(4-ethyl-6-methyl-5-methylideneheptan-2-yl)-7,7,12,16-tetramethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-6-yl acetate
(2e,6r,7s,10e,14e,18r,19s,22e)-2,6,10,15,19,23-hexamethyltetracosa-2,10,14,22-tetraene-1,6,7,18,19,24-hexol
(1r,4e,8e,12r)-1,12-bis[(2s,5r)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-4,9-dimethyldodeca-4,8-diene-1,12-diol
4,4,6b,8a,11,11,12b,14a-octamethyl-1,2,3,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydropicen-3-yl 2-methylbutanoate
(1s,3r,6s,8r,11s,12s,15r,16r)-15-[(2r,4s)-4-ethyl-6-methyl-5-methylideneheptan-2-yl]-7,7,12,16-tetramethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-6-yl acetate
7-(dimethylamino)-1-{4-[(3z)-1-(2-hydroxyethyl)-2,2-dimethylpyrrolidin-3-ylidene]butan-2-yl}-9a,11a-dimethyl-1h,2h,3h,3ah,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-6-one
C33H54N2O2 (510.41850639999996)